Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Core Insights - Jade Biosciences has presented promising preclinical data for JADE101, an anti-APRIL monoclonal antibody aimed at treating IgA nephropathy, indicating its potential as a best-in-class therapy with a favorable pharmacokinetic profile [1][2][3] Preclinical Data Highlights - JADE101 exhibits femtomolar binding affinity to APRIL, approximately 50 fM, which is over 750-fold higher than that of sibeprenlimab, suggesting enhanced efficacy and potential for extended dosing intervals [4] - The pharmacokinetic profile of JADE101 includes a half-life of approximately 27 days in non-human primates, nearly four times longer than sibeprenlimab, and sustained IgA suppression for over 100 days after a single dose [6][7] - JADE101 has shown potent inhibition of APRIL signaling through its receptors, with IC50 values of 1.9 nM for BCMA and 1.03 nM for TACI, indicating strong therapeutic potential [5] Clinical Development Plans - The company plans to initiate a first-in-human trial for JADE101 in healthy volunteers in the second half of 2025, with interim biomarker data expected in the first half of 2026 to guide future dosing strategies [10][14] - JADE101 is designed for convenient subcutaneous dosing, with a profile supporting administration every eight weeks or longer, which is particularly beneficial for patients requiring lifelong treatment [8][14] Company Overview - Jade Biosciences focuses on developing innovative therapies for autoimmune diseases, with JADE101 as its lead candidate targeting IgA nephropathy, a condition affecting approximately 169,000 people in the U.S. [13][15] - The company also has a second development candidate, JADE201, and an undisclosed antibody discovery program, indicating a robust pipeline for future growth [15]